Standout Papers
- Cytochrome P-450 Polymorphisms and Response to Clopidogrel (2008)
- Drotrecogin Alfa (Activated) in Adults with Septic Shock (2012)
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis (2017)
- Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death (2005)
- Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel (2009)
- Baricitinib in Patients with Refractory Rheumatoid Arthritis (2016)
- Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment (2016)
Immediate Impact
69 standout
Citing Papers
Rheumatoid arthritis
2023 Standout
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
2021 Standout
Works of William L. Macias being referenced
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
2017 Standout
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK ) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| William L. Macias | 2751 | 1123 | 1849 | 2595 | 1870 | 90 | 9.7k | |
| Samir M. Parikh | 1995 | 3105 | 1072 | 1555 | 1548 | 127 | 10.4k | |
| Armando D’Angelo | 1260 | 310 | 1515 | 2471 | 1851 | 188 | 9.0k | |
| Armando Tripodi | 3773 | 484 | 1964 | 3544 | 3068 | 336 | 15.1k | |
| Richard H. White | 1188 | 1919 | 809 | 5431 | 3863 | 241 | 15.5k | |
| Jérôme Rossert | 1184 | 4433 | 747 | 1382 | 1138 | 106 | 11.0k | |
| Daniel Deykin | 916 | 507 | 255 | 3926 | 2447 | 155 | 11.7k | |
| John T. Brandt | 573 | 364 | 2081 | 5858 | 3320 | 110 | 10.9k | |
| Siegmund Braun | 659 | 472 | 285 | 3416 | 2035 | 128 | 6.6k | |
| An S. De Vriese | 717 | 3766 | 454 | 1850 | 1428 | 168 | 9.8k | |
| Wendy Lim | 756 | 522 | 604 | 3465 | 2280 | 107 | 9.6k |
All Works
Loading papers...